blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4255486

EP4255486 - TREM2 AGONIST BIOMARKERS AND METHODS OF USE THEREOF [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  08.09.2023
Database last updated on 21.03.2026
FormerThe international publication has been made
Status updated on  14.06.2022
Most recent event   Tooltip11.12.2025New entry: Renewal fee paid 
Applicant(s)For all designated states
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, California 91320 / US
[2023/41]
Inventor(s)01 / ELLWANGER, Daniel C.
Thousand Oaks, California 91320-1799 / US
02 / FOLTZ, Ian N.
Thousand Oaks, California 91320-1799 / US
03 / HASSON, Samuel A.
Thousand Oaks, California 91320-1799 / US
 [2023/41]
Representative(s)Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[2023/41]
Application number, filing date21901658.103.12.2021
[2023/41]
WO2021US72719
Priority number, dateUS202063120986P03.12.2020         Original published format: US 202063120986 P
US202163262943P22.10.2021         Original published format: US 202163262943 P
[2023/41]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2022120373
Date:09.06.2022
Language:EN
[2022/23]
Type: A1 Application with search report 
No.:EP4255486
Date:11.10.2023
Language:EN
The application published by WIPO in one of the EPO official languages on 09.06.2022 takes the place of the publication of the European patent application.
[2023/41]
Search report(s)International search report - published on:US09.06.2022
(Supplementary) European search report - dispatched on:EP10.01.2025
ClassificationIPC:A61K39/395, A61P25/28, C07K16/28, G01N33/68
[2024/46]
CPC:
A61P25/28 (EP,IL,KR); G01N33/6896 (EP,KR,US); C12Q1/6883 (US);
C07K16/2803 (EP,IL,KR); C12Q1/6874 (US); A61K2039/505 (EP,IL,KR);
A61K2039/545 (EP,IL); C07K2317/35 (EP,IL); C07K2317/75 (EP,IL,KR);
C07K2317/90 (EP,IL); C07K2317/92 (EP,IL,KR); C12Q2600/106 (US);
C12Q2600/158 (US); G01N2800/2821 (EP,KR,US); G01N2800/52 (EP,KR,US) (-)
Former IPC [2023/41]A61K39/395, A61P25/28, C07K16/28
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/41]
TitleGerman:TREM2-AGONIST-BIOMARKER UND VERFAHREN ZUR VERWENDUNG DAVON[2023/41]
English:TREM2 AGONIST BIOMARKERS AND METHODS OF USE THEREOF[2023/41]
French:BIOMARQUEURS AGONISTES DE TREM2 ET LEURS MÉTHODES D'UTILISATION[2023/41]
Entry into regional phase03.07.2023National basic fee paid 
03.07.2023Search fee paid 
03.07.2023Designation fee(s) paid 
03.07.2023Examination fee paid 
Examination procedure03.07.2023Examination requested  [2023/41]
28.07.2025Amendment by applicant (claims and/or description)
28.07.2025Date on which the examining division has become responsible
Fees paidRenewal fee
03.07.2023Renewal fee patent year 03
11.12.2024Renewal fee patent year 04
10.12.2025Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A] WO2018195506  (AMGEN INC et al.) [A] 1-5,7-13 * the whole document, in particular claims 69, 70, 77, 78; paragraphs [0024] - [0025]; sequences 330, 331, 339, 340 *
 [Y] US2020277373  (CHEN HANG et al.) [Y] 1-5,7-13 * the whole document, in particular claims 206-211; paragraphs [0548] - [0559] - [ 612] *
 [Y] WO2011143574   [Y] 1-5,7-13 * the whole document, in particular claims 38, 39; table 2 *
International search[XY] US2020277373  (CHEN HANG et al.) [X] 13 * ; paragraphs [0188]-[0190], [0215], [0521], [0527], [0530], [0543]-[0544], [0548], [0555]-[0559], [0564] *[Y] 1-5
 [Y] WO2011143574   [Y] 1-5 * ; page 8, lines 23-30; page 40, lines 9-15 *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.